A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) (NCT07227597)
A Phase 1b/2 Open-label Study Evaluating Different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-Based Regimens in First-line Extensive Stage Small Cell Lung Cancer
🩺 Plain-English Summary (8th-Grade Level)
Researchers are looking for new ways to treat extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC is a type of lung cancer that has spread throughout the lung, to the other lung, or to other parts of the body. A standard (usual) treatment for ES-SCLC uses both chemotherapy and immunotherapy. * Chemotherapy is a treatment that works to destroy cancer cells or stop them from growing. * Immunotherapy is a treatment that helps the immune system fight cancer. Gocatamig and I-DXd (short for ifinatamab deruxtecan) are study medicines. Researchers want to know if giving gocatamig and I-DXd together can treat ES-SCLC. Researchers will also look at giving the study medicines with standard treatment. Gocatamig is a T-cell engager therapy. I-DXd is an antibody drug conjugate. * T-cell engager therapy is a certain type of immunotherapy that uses T-cells to find and destroy cancer cells. * A T-cell is a type of white blood cell, which are cells that help the body fight infection. * An antibody drug conjugate (ADC) is a treatment that attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of combining gocatamig and I-DXd and if people tolerate them together * If people who receive gocatamig and I-DXd have ES-SCLC respond, which means the cancer gets smaller or goes away
Who can join: Review the eligibility criteria below.
Location: Providence Medical Foundation ( Site 0124) — Santa Rosa, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (52 Sites)
Showing the first 25 of 52 sites.
- Providence Medical Foundation ( Site 0124) — Santa Rosa, California
- University of Colorado, Anschutz Cancer Pavilion ( Site 0125) — Aurora, Colorado
- Orlando Health Cancer Institute ( Site 0108) — Orlando, Florida
- Saint Elizabeth Medical Center Edgewood ( Site 0112) — Edgewood, Kentucky
- Washington University School of Medicine ( Site 0134) — St Louis, Missouri
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0101) — Hackensack, New Jersey
- Providence Cancer Institute, Franz Clinic - Eastside ( Site 0107) — Portland, Oregon
- Avera Cancer Institute- Research ( Site 0104) — Sioux Falls, South Dakota
- The University of Tennessee Medical Center ( Site 0120) — Knoxville, Tennessee
- Lt. Col. Luke Weathers, Jr. VA Medical Center ( Site 0133) — Memphis, Tennessee
- SCRI Oncology Partners ( Site 7000) — Nashville, Tennessee
- Houston Methodist Hospital - Houston Methodist Neal Cancer Center ( Site 0113) — Houston, Texas
- University of Virginia Health System ( Site 0122) — Charlottesville, Virginia
- CEMIC ( Site 1903) — Caba., Buenos Aires
- Hospital Austral ( Site 1901) — Pilar, Buenos Aires
- Sanatorio Parque ( Site 1900) — Rosario, Santa Fe Province
- FALP ( Site 0200) — Santiago, Region M. de Santiago
- Pontificia Universidad Catolica de Chile ( Site 0202) — Santiago, Region M. de Santiago
- Bradfordhill ( Site 0201) — Santiago, Region M. de Santiago
- Beijing Cancer Hospital ( Site 1604) — Beijing, Beijing Municipality
- Fujian Provincial Cancer Hospital ( Site 1607) — Fuzhou, Fujian
- Southern Medical University Nanfang Hospital ( Site 1608) — Guangzhou, Guangdong
- Jiangmen Central Hospital ( Site 1611) — Jiangmen, Guangdong
- The First Affiliated Hospital of Nanchang University ( Site 1610) — Nanchang, Jiangxi
- Shanghai East Hospital ( Site 1600) — Shanghai, Shanghai Municipality
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Small Cell Lung Cancer Extensive Stage
- Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer — Tampa, Florida
- DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer — Tampa, Florida
- Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients — Lone Tree, Colorado
- Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) — Dallas, Texas
Explore by condition: All Small Cell Lung Cancer Extensive Stage clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.